Latest Articles

Side Effect Management Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

General Oncology Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Breast Cancer Q&A With Adam M. Brufsky, MD, PhD: Endocrine-based Therapy for HR-positive Metastatic Breast Cancer

Q&A With Adam M. Brufsky, MD, PhD: Endocrine-based Therapy for HR-positive Metastatic Breast Cancer

Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.

Prostate Cancer Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

Sarcoma The Adverse Effects of Sarcoma Treatment in Cancer Survivors

The Adverse Effects of Sarcoma Treatment in Cancer Survivors

Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Lung Cancer Overcoming Resistance to ALK Inhibition in Lung Cancer

Overcoming Resistance to ALK Inhibition in Lung Cancer

The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.

General Oncology Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Renal Cell Carcinoma Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.

Skin Cancer Intratumoral IL-12 Electroporation for Melanoma

Intratumoral IL-12 Electroporation for Melanoma

Intratumoral, or intralesional, therapies are injected directly into the tumor, but can have systemic effects such that some non-injected lesions demonstrate regression.

General Oncology Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

Multiple Myeloma Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.

Prostate Cancer Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.

General Oncology Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Lung Cancer Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters